Related Experiment Video
Updated: Jul 3, 2026
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma
N Niitsu1, H Nakamine, M Okamoto
1Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp
Insights
nm23-H1 expression in classical Hodgkin's lymphoma (CHL) cells is a significant prognostic factor. Both cellular and serum nm23-H1 levels aid in predicting patient outcomes and informing treatment strategies.
Area of Science:
- Oncology
- Hematology
- Molecular Pathology
Background:
- Investigated the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in classical Hodgkin's lymphoma (CHL) patients.
- Utilized immunohistochemistry to analyze cellular markers in CHL.
Purpose of the Study:
- To examine the prognostic significance of nm23-H1 expression in CHL.
- To evaluate the relationship between nm23-H1 expression and patient survival outcomes.
Main Methods:
- Immunohistochemistry was performed on 128 CHL patients (87 nodular sclerosis, 41 mixed cellularity).
- Evaluated expression of CD15, CD20, Ki-67, EBER, TIA-1, and nm23-H1.
- Correlated marker expression with progression-free survival using univariate and multivariate analyses.
Main Results:
- nm23-H1 was expressed in 60% of CHL patients, with higher rates in nodular sclerosis subtypes.
- nm23-H1 expression, along with TIA-1, was identified as an independent prognostic factor for shorter progression-free survival.
- Higher serum nm23-H1 levels correlated with positive cellular nm23-H1 expression and poorer survival.
Conclusions:
- nm23-H1 expression in CHL cells is a valuable prognostic indicator.
- Both cellular and serum nm23-H1 levels are important for predicting CHL patient outcomes.
- Findings support the use of nm23-H1 as a biomarker for guiding CHL treatment strategies.
Background:
We carried out immunohistochemistry to examine the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in patients with classical Hodgkin's lymphoma (CHL).
Patients And Methods:
We evaluated 128 patients with CHL [87 patients with nodular sclerosis (NS) and 41 patients with mixed cellularity (MC)] for CD15, CD20, Ki-67, EBER, TIA-1, and nm23-H1 by immunohistochemistry.
Results:
CD15 was expressed in 79%, CD20 in 11%, Ki-67 in 93%, EBER in 34%, TIA-1 in 11%, and nm23-H1 in 60% of the CHL patients. NS patients showed a significantly higher rate of nm23-H1 expression than MC patients (P < 0.001). The serum nm23-H1 level was significantly higher in patients with positive nm23 expression. Univariate analysis showed that stage IV, poor performance status, low hemoglobin level, low serum albumin level, age of 45 years or older, TIA-1-positive status, and nm23-H1-positive status were associated with significantly shorter progression-free survival. Multivariate analysis with these factors showed TIA-1 and cytoplasmic nm23-H1 expression to be significant and independent prognostic factors.
Conclusions:
Our results indicate that nm23-H1 expression is a prognostic factor for CHL and that it is as important as serum nm23-H1, both of which are useful for planning the treatment strategy.